Vitises Gel & gélules
réguleur de la dépigmentation

La dernière innovation dans le traitement du vitiligo

Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. “A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo”. Arch Dermatol. 2003; 139: 581-5.

Scherschun L, Kim JJ, Lim HW. “Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo”. J Am Acad Dermatol. 2001; 44: 999-1003.

Tobin DJ, Swanson NN, Pittelkow MR, Peters EM, Schallreuter KU. “Melanocytes are not absent in lesional skin of long duration vitiligo”. J Pathol. 2000; 19: 407-16.

Njoo MD, Bos JD, Westerhof W. “Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy”. J Am Acad Dermatol. 2000; 42: 245-53.

Camacho F, Mazuecos J. “Oral and topical L-phenylalanine, clobetasol propionate, and UVA/sunlight. A new study for the treatment of vitiligo”. J Drugs Dermatol. 2002; 1:127-31.

Juhlin L, Olsson MJ. “Improvement of vitiligo after oral treatment with vitamin B12 and folic acid and the importance of sun exposure”. Acta Derm Venereol. 1997; 77: 460-2. Montes LF, Diaz ML, Lajous J, Garcia NJ. “Folic acid and vitamin B12 in vitiligo: a nutritional approach”. Cutis. 1992; 50: 39-42.

Schallreuter KU, Wood JM, Pittelkow MR, Gutlich M, Lemke KR, Rodl W, Swanson NN, Hitzemann K, Ziegler I. “Regulation of melanin biosynthesis in the human epidermis by tetrahydrobiopterin”. Science. 1994; 263: 1444-6.

Jimbow K. “Vitiligo. Therapeutic advances”. Dermatol Clin. 1998; 16: 399-407. Shaffrali F, Gawkrodger D. “Management of vitiligo”. Clin Exp Dermatol. 2000; 25: 575-9.

traitement du vitiligo - © hygiaform - création ataliaweb